Crizotinib, obat baru anti kanker paru

Crizotinib

crizotinib

crizotinib

On August 26, 2011, the U. S. Food and Drug Administration granted accelerated approval to crizotinib (XALKORI

crizotinib

crizotinib

Capsules, Pfizer Inc.) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. The FDA approved the Vysis ALK Break-Apart FISH Probe Kit (Abbott Molecular, Inc.) concurrently with the crizotinib approval. This companion diagnostic test is designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in NSCLC.

The approval was based on two single arm trials, Study A (N = 136 patients) and Study B (N = 119 patients). Crizotinib, 250 mg, was administered orally twice daily to a total of 255 patients with locally advanced or metastatic ALK-positive NSCLC. Demographic analysis from the combined data of these trials noted that the median age was 52 years, 63% of patients were Caucasian, 30% were Asian, 48% were male and 84% had an ECOG performance status of 0 or 1. Fewer than 3% of patients were current smokers. Ninety-six percent had adenocarcinoma, 95% had metastatic disease, and 94% had received prior systemic treatment for NSCLC.
The primary endpoint of both trials was objective response rate (ORR) as assessed by the investigator. In Study A, the ORR was 50% (95% CI: 42%, 59%) with a median response duration of 42 weeks. In Study B, the ORR was 61% (95% CI: 52%, 70%) with a median response duration of 48 weeks. Complete responses were observed in 1% of patients. No differences in ORR by performance status, the number of prior chemotherapeutic regimens, or the percentage of cells found to have the ALK gene rearrangement were noted.
The most common adverse reactions (≥25%) observed in both studies were vision disorder, nausea, diarrhea, vomiting, edema, and constipation. Vision disorders included visual impairment, photopsia, vision blurred, vitreous floaters, photophobia, and diplopia. Grade 3-4 adverse reactions in at least 4% of patients included increased ALT and neutropenia. Crizotinib has been associated with severe, life-threatening, or fatal treatment-related pneumonitis with a frequency of 1.6% in clinical trials. All cases occurred within 2 months after the treatment initiation.
The recommended dose and schedule for XALKORI is 250 mg orally twice daily.
Full prescribing information, including clinical trial information, safety, dosing, drug-drug interactions and contraindications is available at
Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System by completing a form online at http://www.fda.gov/medwatch/report.htm, by faxing (1-800-FDA-0178) or mailing the postage-paid address form provided online, or by telephone (1-800-FDA-1088).
This entry was posted in Obat Baru, Umum on by .

About Webmaster

"My characteristics are:A foundation, order, service, struggle against limits, steady growth. My destiny is to express wonderful organization skills with my ever practical, down-to-earth approach. I’m the kind of person who is always willing to work those long, hard hours to push a project through to completion. My abilities to write and teach may lean toward the more technical and detailed. The positive attitudes; I am one who no doubt, fulfills obligations, and is highly systematic and orderly. I am serious and sincere, honest and faithful. It is my role to help and I am required to do a good job at everything undertake. I may express some of the negative attitudes. The obligations that my face may tend to create frustration and feelings of limitation or restriction. I may sometimes find myself nursing negative attitudes in this regard and these can keep me in a rather low mood. Avoid becoming too rigid, stubborn, dogmatic, and fixed in my opinions. I may have a tendency to develop and hold very strong likes and dislikes, and some of these may border on the classification of prejudice. The negative often produces dominant and bossy individuals who use disciplinarian to an excess. These tendencies must be avoided, hufz..I wish . Finally, I must keep my eye on the big picture and not get overly wrapped up in detail and routine. My desire in life is personal expression, and generally enjoying life to its fullest. I want to participate in an active social life and enjoy a large circle of friends. I want to be in the limelight, expressing my artistic or intellectual talents. Word skills may be my thing; speaking, writing, acting. In a positive sense is friendly, outgoing and always very social. I have a decidedly upbeat attitude that is rarely discouraged; a good mental and emotional balance. My Soul Urge gives intuitive insight, thus, very high creative and inspirational tendencies. The truly outstanding trait shown is that of self-expression, regardless of the field of endeavor. On the negative side, I may at times become too easygoing and too optimistic, tending to scatter forces and accomplish very little. Often, the excessive 3 energy produces non-stop talkers. Everyone has faults, but my urge doesn't appreciate having these pointed out. I dream of being a leader and one who is in charge. I want to be known for my courage, daring, and original ideas. I seek unconquered heights. People may get a first impression that I am very aggressive and sure of myself.

Leave a Reply

Your email address will not be published. Required fields are marked *